Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

Our symposia are designed to help keep healthcare professionals informed about the latest advancements in ECP. If you missed our symposia in 2024, take a look at the recordings on-demand below.

Upcoming Symposia
Past Symposia

Oct 17, 2025

Symposium at EBMT NAP: Advantages of ECP based combinations for the treatment of GvHD

Birmingham, UK

Oct 16, 2025

EORTC 2025 Clinical Symposium: Advancing knowledge on ECP in CTCL

Athens, Greece

Filter by:

Oct 2, 2025

EBMT 2025 TCWP Clinical Symposium: ECP and Ruxolitinib combination in severe steroid—refractory acute GvHD

Dubrovnik, Croatia

Sep 25, 2025

COSTEM 2025: Meet The Expert Session

Berlin, Germany

Sep 18, 2025

DGTI 2025 Clinical Symposium: A focus on the possible MOA: ECP in multiple indications. This event is in German

Mannheim, Germany

Sep 12, 2025

ADO 2025 Clinical Symposium: Extracorporeal photopheresis current status. This event is in German

Essen, Germany

Sep 5, 2025

EBMT 10th International Transplant and Cellular Therapy Course Clinical Symposium: Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy

University of Barcelona – Faculty of Medicine, Spain

May 5, 2025

GITMO 2025 Clinical Symposium: cGVHD: Evidence and new experiences with ECP

Centro Congressi Lingotto, Turin, Italy

Mar 30, 2025

EBMT 2025 Nurse Symposium: Delivering Therakos ECP: Best Practice in 2025

Florence, Italy

View Symposium

Mar 30, 2025

EBMT 2025 Clinical Symposium: Therakos ECP: A Backbone for GvHD Therapy

Florence, Italy

View Symposium

Oct 24, 2024

Therakos Meet The Expert Session at COSTEM 2024

Virtual & Hotel nhow Berlin, Germany

Oct 11, 2024

EORTC 2024 Clinical Symposium: Durability of Response – An important parameter in the management of CTCL

Beaulieu Conference Center, Lausanne, Switzerland

Sep 26, 2024

ADO 2024 Clinical Symposium: ECP as monotherapy and combination partner

Congress Centrum Würzburg, Germany

Sep 12, 2024

16th International Congress on Lung Transplantation: ECP in Lung Transplantation: From treating to preventing – What? How? What for?

Salle Louis Armand, Union Internationale des Chemins de Fer, Paris, France

Sep 12, 2024

DGTI 2024 Clinical Symposium: ECP best practice and possible future perspectives. This event is in German

Düsseldorf, Germany

Sep 6, 2024

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

University of Barcelona – Faculty of Medicine Barcelona, Spain

Apr 16, 2024

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

Glasgow, Scotland

View Symposium

Apr 12, 2024

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

Prague, Czech Republic

View Symposium

Oct 19, 2023

COSTEM 2023: Meet The Expert Session

Berlin, Germany

View Symposium

EBMT 2024 Highlight Report

DISCOVER MORE

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

Symposium at EBMT NAP: Advantages of ECP based combinations for the treatment of GvHD

EORTC 2025 Clinical Symposium: Advancing knowledge on ECP in CTCL

EBMT 2025 TCWP Clinical Symposium: ECP and Ruxolitinib combination in severe steroid—refractory acute GvHD

COSTEM 2025: Meet The Expert Session

DGTI 2025 Clinical Symposium: A focus on the possible MOA: ECP in multiple indications. This event is in German

ADO 2025 Clinical Symposium: Extracorporeal photopheresis current status. This event is in German

EBMT 10th International Transplant and Cellular Therapy Course Clinical Symposium: Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy

GITMO 2025 Clinical Symposium: cGVHD: Evidence and new experiences with ECP

EBMT 2025 Nurse Symposium: Delivering Therakos ECP: Best Practice in 2025

EBMT 2025 Clinical Symposium: Therakos ECP: A Backbone for GvHD Therapy

Therakos Meet The Expert Session at COSTEM 2024

EORTC 2024 Clinical Symposium: Durability of Response – An important parameter in the management of CTCL

ADO 2024 Clinical Symposium: ECP as monotherapy and combination partner

16th International Congress on Lung Transplantation: ECP in Lung Transplantation: From treating to preventing – What? How? What for?

DGTI 2024 Clinical Symposium: ECP best practice and possible future perspectives. This event is in German

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

COSTEM 2023: Meet The Expert Session

EBMT 2024 Highlight Report

Discover more

Courses

Webinars

Speaker Meetings

Ask the Expert

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS